THCA Therapeutics reached an important milestone when Dr. Joel Gagnier, a clinical epidemiologist and researcher at Western University, responded positively after reviewing the company’s vision. In his response, Dr. Gagnier expressed enthusiasm for the scientific concept, indicated his interest in collaborating, and proposed exploring a potential role as Chief Scientific Officer, including discussions regarding long-term equity participation. This represented the company’s first expression of interest from an established academic researcher in joining the leadership team and marked a significant step toward building a multidisciplinary scientific foundation for THCA Therapeutics.